Schlieren, Switzerland – July 28, 2020 InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company company has completely reengineered its live microtissue shipping technology and is introducing InFloat™: a unique shipping system designed to keep plates of assay-ready 3D InSight™ microtissues upright, secure, and at physiological temperatures suitable for live cell cultures during domestic and international transit.
InSphero, the first biotechnology company to successfully transport living 3D cell-based spheroid models using global express delivery services, guarantees that its assay-ready microtissues stay alive and preserve their physiological function under often harsh conditions during shipments that can require several transit days, depending on the destination. The new, patent-pending InFloat™ packaging system employs a simple, but ingenious approach, in which a watertight spherical container floats on water inside a cubical container and can freely rotate, so that the precious microtissue cargo inside always remains in a stable, upright position.
“One of the biggest challenges of shipping live 3D cell cultures is that we simply can’t control what happens to our boxes of microtissues after they leave our bioproduction facilities,” says InSphero CEO and Co-Founder Jan Lichtenberg, PhD. “Our InFloat™ shipping system reduces shipping risks and uncertainty by allowing our carefully packaged plates of microtissues to literally float safely on water until they reach their destination.”
InSphero, which develops 3D cell models comprising primary human cells that are used by global pharmaceutical companies for drug discovery and safety testing, is now delivering plates 3D InSight™ Liver and Islet Microtissues in the new InFloat™ shipping system.
For more information about InFloat™ technology and InSphero live microtissue shipping, visit, visit
About InSphero
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.
Learn more at www.insphero.com. Follow the company on Twitter and LinkedIn.
Media Contact
Frank Junker, PhD
Chief Business Officer
InSphero AG
Phone +41 44 5150490
frank.junker@insphero.com